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ABSTRACT
Introduction: Tuberculosis (TB) have demonstrated a global increase since 1990 along with the increase of 
world’s population and the transmission of human immunodeficiency virus (HIV). Anti-tuberculosis drugs are 
very effective, but it may cause drug-induced hepatitis (DIH). The aim of this study was to assess the prevalence 
and association of several risk factos with the occurence of drug-induced hepatitis in HIV-positive tuberculosis 
patients.
Method: We conducted a retrospective case-control study based on medical records of HIV-positive TB 
patients who seek medical attention to HIV Referral Center at Cipto Mangunkusumo Hospital between July 
2008 and December 2010. Overall, we enrolled 168 medical records with 42 cases and 126 controls. Chi-square 
and logistic regression test analysis were conducted for analyzing risk factors of drug-induced hepatitis in HIV-
positive tuberculosis patients.
Results: Drug-induced hepatitis were found in 42 (8.04%) patients.The prevalence of DIH was highest 
among 35 (25.2%) male patients, aged < 35 years old  in 32 (26.0%) patients, with albumin level < 3.5 g% in 
10 (11.2%) patients, body mass index (BMI) < 18.5 kg/m2 in 14 (18.4%) patients, CD4+ count < 100 cells/mm3 
in 29 (24.4%) patients, and those who received rifampicin (R), isoniazid (H), and pirazinamid (Z) regiments 
for their anti-tuberculosis drugs 24 (31.2%) patients. No risk factors were found to have statistically significant 
association with DIH.
Conclusion: The prevalence of DIH is quite high. Although no risk factor was found statistically significant, but 
evaluation and liver biochemical examination should be carried out regularly in patients with DIH risk factors.
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ABSTRAK
Pendahuluan: Tuberkulosis (TB) meningkat secara global sejak tahun 1990-an, seiring dengan peningkatan 
populasi di dunia dan penularan ‘human immunodeficiency virus’ (HIV). Pengobatan dengan obat anti-
tuberkulosis sangat efektif, namun dapat menyebabkan gangguan pada hati  atau hepatitis imbas obat. Tujuan 
penelitian ini adalah untuk menilai prevalensi dan hubungan beberapa faktor risiko dengan kejadian hepatitis 
imbas obat pada pasien TB-HIV.
Metode: Dilakukan studi kasus kontrol dengan menelusuri data rekam medik pasien TB yang mengidap 
HIV-positif yang datang ke Kelompok Studi Khusus (POKDISUS) Rumah Sakit Cipto Mangunkusumo sejak 
Juli 2008 sampai Desember 2010. Digunakan uji kai kuadrat dan regresi logistik pada 168 data rekam medik 
sebagai sampel yang terdiri dari 42 kasus dan 126 kontrol untuk menilai faktor risiko terjadinya hepatitis imbas 
obat pada pasien TB-HIV.
Hasil: Hepatitis imbas obat ditemukan pada 42 (8,04%) pasien. Prevalensi hepatitis imbas obat tertinggi 
ditemukan pada 5 pasien pria (25,2%), pasien usia < 35 tahun sejumlah 32 (26,0%) orang, pasien dengan kadar 
albumin < 3,5 g% sejumlah 6 (11,2%) orang, pasien dengan indeks masa tubuh < 18,5 kg/m2 sejumlah 14 (18,4%), 
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pasien dengan kadar CD4+ < 100 cells/mm3 sejumlah 29 (24,4%) orang, dan pada mereka yang mendapatkan 
regimen obat anti-tuberkulosis (OAT) rifampisin, isoniazid, dan pirazinamid sejumlah 25 (31,2%) pasien. Tidak 
satupun dari faktor risiko tersebut terbukti memiliki hubungan bermakna dengan kejadian hepatitis imbas obat.
Simpulan: Prevalensi hepatitis imbas obat masih cukup tinggi. Meskipun tidak satupun faktor dalam penelitian 
ini terbukti bermakna berhubungan dengan kejadian hepatitis imbas obat, namun evaluasi dan pemeriksaan 
biokimiawi fungsi hati tetap harus rutin dilakukan pada pasien yang memiliki faktor risiko untuk mengalami 
hepatitis imbas obat.
Kata kunci: hepatitis imbas obat, tuberkulosis, human immunodeficiency virus
INTRODUCTION
Tuberculosis (TB) affects one third of the 
world’s population.1 As an immune-related disease, 
Mycobacterium tuberculosis (MTB) infection is 
facilitated by immunocompromised status. It causes 
individuals with immune deficiency to develop a greater 
risk of TB. One of the high-risk group is individual with 
human immunodeficiency virus-infection.2 
The World Health Organization (WHO) estimates 
that TB is the cause of death for 11% of all acquired 
immunodeficiency syndrome (AIDS) patients. In 2006, 
it was estimated that over 700,000 people had suffered 
from HIV-associated TB; of whom, about 200,000 
have died.3 Anti-tuberculosis treatment with isoniazid, 
rifampicin and pyrazinamide are very effective.1 
In the United States, the percentage and absolute 
number of patients with TB disease who are HIV-1 
infected is declining because of improved infection-
control with anti-tuberculosis treatment equiped by 
voluntary counseling and testing.2 Therefore, many 
efforts regarding this issue have been conducted, 
which include screening for TB in people living with 
HIV, isoniazid preventive therapy (IPT), and infection 
control.3 Nevertheless, treatment with anti-tuberculosis 
drugs may also cause hepatotoxicity. 
It has been known that individuals with immune 
deficiency are more likely develop drug-induced 
hepatitis (DIH) compared to those of normal population. 
Marzuki et al, has shown that HIV positivity was a 
significant factor for developing anti-tuberculosis 
DIH.1 Dealing with this problem, Center for Disease 
Control and Prevention (CDC), the National Institutes 
of Health, and the HIV Medicine Association (HIVMA) 
and Infectious Diseases Society of America (IDSA) 
recommend to conduct gradual liver function test for 
HIV patients receiving treatment of anti-tuberculosis.2 
Sufficient information about the prevalence and 
associated factors of drug-induced hepatitis in TB-HIV 
patients is also required for establishing early diagnosis 
and providing prompt treatment. Therefore, this study 
aim was to obtain the prevalence and several factors 
associated with DIH in HIV-positive tuberculosis 
patients in Cipto Mangunkusumo Hospital.
METHOD
Between July 2008 and December 2010, a retros-
pective case-control study was conducted at HIV 
Referral Centre of Cipto Mangunkusumo Hospital 
that served as referral and treatment centers for HIV 
and TB in Indonesia. This study attempted to explore 
whether several demographic, clinical, laboratoric 
characteristics had a correlation with DIH among 
patients with co-infection HIV and tuberculosis who 
received anti-tuberculosis regiments. 
Medical records of 372 HIV-positive TB patients at 
the outpatient clinic who were having anti-tuberculosis 
therapy were evaluated. Tuberculosis was diagnosed 
based on clinical criteria (chronic cough which last 
more than two weeks, prolonged fever, extreme weight 
loss, and night sweating), as well as radiological 
and laboratoric (alcohol acid fast bacilli) evidence; 
while hepatotoxicity was diagnosed on the present of 
nausea, vomitus, weakness, and jaundice along with 
high concentration of AST/ALT. Additional inclusion 
criteria included patients whose medical file showed 
normal results of AST/ALT test before the treatment 
of anti-tuberculosis regiments. Medical records with 
uncomplete data or elevated AST/ALT level before 
starting tuberculosis treatment were excluded from 
the study. 
This was a retrospective case-control study since 
there was a time interval between the prescription 
of anti-tuberculosis regiment and the occurence of 
DIH. We took the equal population, i.e. HIV-infected 
individuals as the control group in order to minimize 
bias (ratio 1 : 3).
A total of 372 medical records of patients co-
infected with HIV and tuberculosis receiving anti-
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tuberculosis regiment were collected. Among them, 
42 subjects developed DIH; while the other 330 subjects 
did not present those effects. Of those who did not 
develop DIH, 126 subjects were randomly selected as 
the control group. Data was cleaned for inconsistencies 
and missing values, which subsequently was analyzed 
using SPSS 16.0 statistical software. Chi-square 
test was used to evaluate the association between 
the abovementioned characteristics and the prevalence 
of DIH in HIV-positive TB patients who received anti-
tuberculosis regiment. All variables with significant 
association in bivariate analysis (p < 0.25) were 
Table 1. Bivariate analysis on demographic and clinical characteristics associated with DIH in HIV-
positive tuberculosis  patients
Variable DIH (n = 42)n (%)
Non DIH (n = 126)
n (%)
OR
(95% CI) p*
Age (year)
< 35
≥ 35
32 (26.0)
10 (22.2)
91 (74.0)
35 (77.8)
0.812
(0.361-1.826) 0.615
Sex
Male
Female
35 (25.2)
7 (24.1)
104 (74.8)
22 (75.9)
0.945
(0.372-2.403) 0.906
Extrapulmonary tuberculosis
Yes
No
1 (11.1)
41 (25.8)
8 (88.9)
118 (74.2)
0.360
(0.044-2.964) 0.453
Pulmonary tuberculosis
Yes
No
27 (24.8)
15 (25.4)
82 (75.2)
44 (74.6)
0.966
(0.466-2.004) 0.926
Pulmonary and extrapulmonary 
tuberculosis
Yes
No
12 (31.6)
30 (23.1)
26 (68.4)
100 (76.9)
1.538
(0.694-3.412)
0.287
Milliary tuberculosis
Yes
No
2 (16.7)
40 (25.6)
10 (83.3)
116 (74.4)
0.580
(0.122-2.760) 0.489
BMI (kg/m2)
< 18.5
≥ 18.5
14 (18.4)
13 (25.5)
62 (81.6)
38 (74.5)
0.660
(0.280-1.554)
0.340
Anti-tuberculosis regiment
RHZE
Yes
No
RHZ
Yes
No
22 (29.3)
20 (21.5)
24 (31.2)
18 (19.8)
53 (70.7)
73 (78.5)
53 (68.8)
73 (80.2)
1.836
(0.906-3.721)
1.836
(0.906-3.721)
0.244
0.089
BMI: body mass index; RHZE: rifampicin, isoniazid (INH), pyrazinamide, etambutol; DIH: drug-induced hepatitis; 
*chi-square test
candidates to be included in the final multivariate 
analysis by using logistic regression test.
RESULTS
Three hundred and sixty two patients were enrolled 
in the study. Among them, 42 subjects developed 
DIH (8.04%). Based on demographic characteristics, 
the prevalence of DIH was highest among male 
subjects (25.2%) and aged < 35 years old (26.0%). 
Considering the baseline clinical characteristics, 
this study showed that DIH were more frequent 
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among those of pulmonary tuberculosis group and 
low body mass index (BMI) < 18.5 kg/m2. Most of 
them had albumin level of < 3.5 g% (11.2%), CD4+ 
counts of < 100 cells/mm3 (24.4%), and received RHZ 
regiments for their anti-tuberculosis treatment (31.2%), 
as seen in Table 1. Statistical analysis (bivariate and 
multivariate) did not found any risk factors to be 
statistically significant as risk factor for DIH, as seen 
in Table 2 and 3.
DISCUSSION
In the present study, we explored demographic, 
clinical, and laboratoric characteristics to assess 
whether those factors are associated with DIH in 
HIV-positive TB patients who were seeking medical 
treatment at HIV referral center Cipto Mangunkusumo 
Hospital. 
There are several previous reports which focused 
on assessing factors associated with DIH; however, 
those reports have not demonstrated results on specific 
population such as HIV-related TB patients, HIV-
positive TB patients were only placed into subgroup to 
be compared with another group.1,4-8 Results revealed 
from those studies stated that HIV positivity in patients 
receiving anti-tuberculosis agent was significant for 
higher risk of developing DIH.
Based on demographic profile, subjects of this study 
were mostly male patients among both group (25.2% of 
case group and 74.8% of control group). It is consistent 
with a study in Brazil, which even demonstrated higher 
percentage (56.1% of case group and 77.6% of control 
group). This study results were in contrast to another 
study comparing the incidence of hepatotoxicity 
between group of patients receiving anti-tuberculosis 
and antiretroviral drugs, which their multivariate 
analysis showed significant correlation between sex 
characteristic and the incidence of hepatotoxicity with 
a greater risk in female patients (p = 0.219; OR = 4.2).9 
We also found that patients aged < 35 years old 
(26.0%) were most likely to develop DIH. The findings 
are consistent with a study in Ethiopia comparing 
the incidence based on HIV status.10 Similar study in 
Thailand also found that their subject mostly belong 
to the mean age of 35 years old.9 However, these 
findings were contrast to several studies showing that 
age was found to be a risk factor for DIH. Another 
study has reported that hepatotoxicity ranges from 22 
to 33% in those subjects who were older than 35 years, 
compared with 8 to 17% in those who were younger 
than 35 years.11
It has been known that there is an association 
between a low BMI with the development of TB in HIV 
patients. First, TB could lead to malnutrition through 
Table 2. Bivariate analysis on laboratory findings associated with DIH in HIV-positive tuberculosis patients
Variable DIH (n = 42)n (%)
Non DIH (n = 126)
n (%)
OR
(CI 95%) p*
Hepatitis B (HBsAg)
Yes
No
6 (37.5)
36 (23.8)
10 (62.5)
115 (76.2)
1.917
(0.651-5.639) 0.183
Hepatitis C (anti-HCV)
Yes
No
18 (20.7)
24 (18.0)
69 (79.3)
56 (70.0)
0.609
(0.301-1.233) 0.166
HBsAg and anti-HCV
Yes
No
0 (0.0)
42 (25.8)
5 (100.0)
121 (74.2)
- 0.333
Albumin (g/dL)
< 3.5
≥ 3.5
10 (11.2) 
6 (11.5)
79 (88.8)
46 (88.5)
0.970
(0.331-2.845) 0.956
CD4+ (cell/mm3)
< 100
100-200
29 (24.4)
4 (13.8)
90 (75.6)
25 (86.2)
2.014
(0.647-6.268)
0.220
AAFB
Positive
Negative
3 (20.0)
14 (20.6)
12 (80.0)
54 (79.4)
0.964
(0.239-3.891)
0.959
DIH: drug-induced hepatitis; HBsAg: hepatitis B surface antigen; anti-HCV: anti-body hepatitis C virus; AAFB: alcohol acid fast 
bacilli; *chi-square test
Table 3. Multivariate analysis on factors associated with DIH in 
HIV-positive tuberculosis patients
Variable OR (95% CI) p*
Hepatitis C 0.036-1.517 0.381
Hepatitis B 0.601-5.442 0.292
CD4+
RHZE
RHZ
0.332-1.885
0.906-3.721
0.906-3.721
0.597
0.999
0.999
RHZE: rifampicin, INH, pyrazinamide, etambutol; DIH: drug-induced hepatitis; 
*logistic regression test
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anorexia. Increased metabolic rate, malabsorption and 
any immune impairment as a result of HIV/AIDS leads 
to malnutrition.12,13 
On the other hand, malnutrition in HIV patients 
can aggravate immune deficiency and subsequently 
increase the risk of active TB. As we have known, 
malnutrition can cause liver damage through a chronic 
process. Theoretically, it explains why drug-induced 
hepatotoxicity occurs more easily in co-infected 
patients with lower BMI. In this study, the results 
based on baseline clinical characteristics showed that 
DIH were more frequent among those of pulmonary 
tuberculosis group and low BMI (< 18.5 kg/m2). 
However, in this study, there was no significant 
difference in BMI among subjects in the case group, 
i.e. there were 14 patients who had BMI lower than 
18.5 kg/m2 and 13 patients with BMI more than 18.5 
kg/m2. A larger percentage of low BMI in patients 
presented with hepatotoxicity was found in a study 
among Ethiopian patients, i.e. 58.7% of 184 patients. 
Similar results were also found for other studies in 
Ethiopia and Thailand.9,10 
It might occur since the high incidence of TB in 
HIV patients was mostly found in subjects with low 
BMI and pulmonary TB is the most common type of 
TB found in HIV patients. This study showed similar 
findings to one study in Ethiopia based on CD4+ 
counts, which demonstrated that the distribution of 
anti-tuberculosis DIH were mostly found among 
them with CD4+ counts < 100 cells/mm3 (24.4%).10 
It could be explained since CD4+ counts < 100 cells/
mm3 represents worse immune deficiency. Based 
on the anti-TB regiment, this study showed that 
the high incidence of TB in HIV patients was mostly 
found among subjects receiving rifampicin, isoniazid 
(INH), and pyrazinamide (31.2%); while other studies 
found that the incidence mostly belongs to the group 
receiving anti-tuberculosis regiments of streptomycin, 
rifampicin, INH, and pyrazinamide (SRHZ).10 
HIV-infected individuals are not only at risk for 
tuberculosis but also at risk for hepatitis B and or C 
infection. These infections attack the liver and may 
influence susceptibility of the organ to injury caused 
by hepatotoxic drugs such as anti-tuberculosis and 
antiretroviral drugs.
 HIV positivity has been found to be a risk factor 
for DIH and the occurrence of hepatitis C co-infection 
has augmented the condition. In contrast, another study 
showed that hepatitis B infection were not found to be 
statistically significant with DIH.4 It is consistent with 
these findings that 18 of 42 co-infected patients with 
DIH had hepatitis C infection, while only 6 of them had 
hepatitis B infection. Another study found that HIV-
positive TB patients who received anti-tuberculosis 
regiment and developed DIH showed a significantly 
higher frequency of co-infection with hepatitis B or 
C on bivariate and multivariate analysis (p < 0.001) 
with an odds ratio of 21.73 (95% CI = 2.71-174.18).14 
Multivariate and bivariate analysis in this study 
showed that no factor was statistically significant 
regarding its association with DIH in HIV-positive TB 
patients. Retrospective data collection is a limitation of 
this study. It enables the occurence of bias since those 
medical records were filled in by different physicians. 
Moreover, there were some medical records with 
incomplete data. However, the prevalence of DIH in 
some patients calls for greater concern since tuberculosis 
is a major problem in HIV; while on the other hand, 
anti-retroviral and anti-tuberculosis drugs has a sinergic 
hepatotoxicity effect. Therefore, in the near future, it is 
highly appreciated for gastroentero-hepatologist to be 
involved in the integrated management of HIV patients. 
Further cohort study is recommended to obtain more 
reliable information about risk factors associated with 
the incidence of DIH and early detection for hepatic 
injury in HIV-positive TB patients who are on anti-
tuberculosis treatment. This allows physician to be 
aware when prescribing anti-tuberculosis regiments to 
HIV-positive TB patients who have risk factors for DIH.
CONCLUSION
The prevalence of DIH is quite high, which was 
found mostly in male patients, and those with low 
albumin, BMI, and CD4+ count. Despite no significant 
risk factors were found to be associated with the 
incidence of DIH in HIV patients, evaluation and liver 
bio-chemical examination still should be carried out 
regularly in HIV patients receiving anti-tuberculosis 
regiments.
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